Metreleptin not checked

Chiesi Farmaceutici S.p.A.

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
2 active
3 in total · 2 in the EU

What this is

How it works
Leptin Analog FDA class
How it’s given
“Metreleptin is a recombinant human leptin analog that is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency”In the company’s words, NCT06484868 on ClinicalTrials.gov
Tested for
Partial Lipodystrophy, Familial Partial Lipodystrophy
Main trialPhase 4
“This is an Open Label, Phase IV, Post Authorisation Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in people with Partial Lipodystrophy”In the company’s words, NCT06484868 on ClinicalTrials.gov

Other drugs for Familial Partial Lipodystrophy

All 2 drugs for Familial Partial Lipodystrophy

Coming up2

Changes2

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 4Recruiting Feb 2028 Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Phase 3Recruiting Mar 2028 Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Phase 3Completed 14 Jul 2026 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Metreleptin

Following is part of Solo: you see every change to Metreleptin the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in